Robert I Blum

CYTK CEO Robert I Blum sells 7,500 shares at $70.46 via 10b5-1 plan; stock down 11.0% from 52-week high.

Robert I Blum sold 7,500 shares (7.5K shares) of CYTOKINETICS INC at $70.46 on 2026-06-15, reducing holdings from 392,830 to 385,330 shares, a net change of -1.9% vs pre-transaction holdings. This sale was executed under a pre-arranged 10b5-1 trading plan, making it scheduled rather than discretionary. The current stock price of $71.38 is -11.0% from the 52-week high of $80.20, and the company remains unprofitable with a net income of $-206.0M in its latest full fiscal year, though it posted strong annual revenue growth of +376.6%. His prior trades at CYTK show mixed outcomes: two prior measurable sales produced 30-day returns of +5.3% and -10.0% respectively, with 90-day returns of +14.8% and -18.6%, providing no clear directional signal. The scheduled nature of this transaction under a 10b5-1 plan means it reflects a pre-commitment to a divestment schedule rather than a response to current market or company conditions.

CEO Robert I Blum sold 7,500 shares (7.5K shares) of CYTK at $77.21 (scheduled 10b5-1 plan)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares (7.5K shares) worth $579,075.00 ($579.1K) on 2026-05-27 as part of a pre-arranged 10b5-1 trading plan, reducing holdings from 400,330 shares (400.3K shares) to 392,830 shares (392.8K shares). The sale occurred near the 52-week high of $80.20 (stock is -4.2% from peak), following a strong 30-day gain of +26.6% and 90-day gain of +23.4%. Because this transaction is scheduled under a 10b5-1 plan rather than discretionary, it reflects pre-determined execution rather than a current market judgment. The company is unprofitable (net income $-206.0M in latest full year) despite significant revenue growth of +376.6% year-over-year, leaving operational cash generation as a key consideration for investors monitoring executive position changes.

CEO Robert I Blum sold 7,500 shares at $77.92 via 10b5-1 plan; stock near 52-week high ($80.20)

Robert I Blum, President & CEO of Cytokinetics Inc, sold 7,500 shares for $584,400 through a pre-arranged 10b5-1 trading plan on 2026-05-14, reducing holdings to 400,330 shares. This is a scheduled, non-discretionary transaction executed near the stock's 52-week high of $80.20 (current price $78.64 is -2.0% from peak), suggesting the sale was mechanically triggered by plan parameters rather than a discretionary timing decision by the insider. While Blum's historical sell track record shows a 50.00% well-timed rate with negative average returns at 30 days (-0.2%) and 90 days (-3.4%), the 10b5-1 framework precludes inferring conviction or strategic intent from this particular transaction. Investors should note the company remains deeply unprofitable with -$206.0M net income despite exceptional 376.6% annual revenue growth, making the valuation and execution timing context less material than the mechanical nature of the trade plan.

Cytokinetics CEO sells 36.6K shares for $2.3M; 5 of 5 prior CYTK sales were well-timed at 90d mark

Robert I Blum, President & CEO, executed 2 separate sales totaling 36,601 shares for $2,274,752.15 at $62.15 per share on 2026-03-17. His holding declined from 466,931 to 430,330 shares (-7.8%). His prior trade history at CYTK is notable: all 5 preceding sales at this ticker were well-timed, with 90-day returns of -18.6%, -22.5%, -23.0%, -25.4%, and -26.0% respectively—every sale preceded material declines. His cross-ticker track record shows a 58.33% well-timed rate on 18 prior sells with an average 90-day return of -8.0%, suggesting selective accuracy in exit timing. With CYTK trading near flat on a 90-day basis (-0.0%) but down 6.1% over 30 days and 11.3% from its 52-week high of $70.10, the pattern of consistent prior well-timed exits invites attention to whether this sale signals forward-looking conviction. The company remains unprofitable (net income: $-306,178,000.00 in the latest period) despite strong revenue growth of +376.6%, creating a backdrop where insider conviction, whether bullish or cautionary, carries weight.

CYTK President & CEO Blum sold 15,000 shares at $40.75 on 2025-03-31; stock now -46.4% from 52-week high

Robert Blum, President & CEO of Cytokinetics, sold 15,000 shares (15.0K shares) for $611,250.00 at $40.75 on March 31, 2025, reducing his holdings by 3.4% to 427,629 shares. The sale follows aggressive selling activity at this ticker: four prior sales in the first two weeks of March 2025, plus another on March 17, suggesting an active unwind pattern within a concentrated period. Against the company's fundamentals—which show net income of $-160,545,000.00 and recent quarterly revenue of $463,000.00 against a $4.8B market cap—the stock has declined 46.4% from its 52-week high of $75.05 and fallen 12.6% in the prior 30 days. His cross-ticker track record shows a 50.00% well-timed rate on prior sells (higher is better), but at CYTK specifically, only 1 of 1 measurable prior sells was poorly timed, with a 90-day return of +5.1% in his August 2024 sale. The rapid succession of recent sales by the CEO at a stock trading near its 52-week lows warrants investor attention to the underlying operational drivers."

CYTK President & CEO Blum sells 25,000 shares at $44.65; stock now -40.2% from 52-week high

Robert I. Blum, President & CEO of Cytokinetics, sold 25,000 shares (25.0K shares) at $44.65 on 2025-03-17, reducing his holdings by 6.9% to 339,181 shares (339.2K shares). The current price of $44.91 sits -40.2% from the 52-week high of $75.05, and his prior trades at CYTK show mixed outcomes: his 2024-07-30 sale preceded a -12.2% 90-day decline (well-timed), while his 2024-08-12 sale was followed by a +5.1% gain (poorly-timed). The company remains unprofitable with net income of $-160,545,000.00 ($-160.5M) over its most recent full fiscal year, though revenue grew +145.3% year-over-year, indicating a pre-profitability growth-stage biotech. The timing of this sale warrants attention given the 40%+ drawdown from peak valuations and the insider's mixed track record at this specific ticker.

CYTK CEO Robert Blum sells 12,648 shares at $44.38; stock down -40.2% from 52-week high of $75.05

Robert I Blum, as President & CEO, sold 12,648 shares of Cytokinetics on 2025-03-17 at $44.38, reducing his holdings to 326,533 shares (-3.7% of pre-transaction holdings). The stock is currently trading at $44.91, down -40.2% from its 52-week high of $75.05 and -2.7% over the past 30 days. At the same-ticker level, Blum has executed 5 trades at CYTK in recent months (three sales in early March 2025 and two prior sales in mid-2024), with mixed timing outcomes: his August 2024 sale resulted in a 90-day +5.1% return (poorly timed), while his July 2024 sale saw a 90-day -12.2% return (well-timed). The company is unprofitable with a -$160.5M net income on quarterly revenue of $463.0K, though it has achieved +145.3% annual revenue growth. The pattern of multiple concentrated sales from the CEO within a short window (three sales within 12 days) against a deteriorated valuation backdrop warrants attention to liquidity needs and insider confidence signals at the top of the organization.

CEO Blum sells 16,970 shares of CYTK at $43.44; stock down 42.1% from 52-week high and company unprofitable

Blum Robert I, President & CEO, sold 16,970 shares (17.0K shares) of CYTOKINETICS INC at $43.44 on 2025-03-06, reducing his holdings by 4.5% to 364,181 shares (364.2K shares). The stock is currently -42.1% from its 52-week high of $75.05 and has declined 13.8% over 30 days and 14.8% over 90 days. Across his prior same-ticker history at CYTK (5 prior trades), timing outcomes are mixed: 2 of 4 prior sells with measurable 90-day outcomes were well-timed (selling before declines), while 2 were not. The company remains unprofitable with net income of $-160,545,000.00 ($-160.5M) in its most recent full fiscal year, though annual revenue growth reached +145.3%. This sale occurs as the stock trades well below peak valuations, and the insider retains substantial holdings, but the recent weak price action and unresolved profitability questions warrant monitoring of future trading activity and quarterly results.

CEO Blum sells 25,000 CYTK shares at $43.23; stock down 41.5% from 52-week high, company unprofitable with $-160.5M net loss

Robert I Blum, President & CEO, sold 25,000 shares of CYTOKINETICS INC at $43.23 on 2025-03-05, reducing his holdings from 406,151 to 381,151 shares (a 6.2% reduction). The transaction occurs against a backdrop of significant recent price weakness: the stock is currently trading at $43.88, down 41.5% from its 52-week high of $75.05, with declines of 9.5% over the past 30 days and 12.9% over 90 days. CYTOKINETICS remains unprofitable, having reported a net loss of $-160.5M on quarterly revenue of $463,000, though annual revenue growth stands at +145.3% year-over-year. His prior five sales at CYTK show mixed timing results: only 2 of 5 were well-timed at the 90-day mark, with returns ranging from +9.2% to -3.5% in the 30-day window and -12.2% to +6.2% over 90 days. The proximity of this sale to the stock's 52-week peak in the recent past and the company's ongoing unprofitability merit investor attention to both near-term execution trends and the company's path to profitability.

CYTK CEO Robert Blum sells 11.5K shares at $55.17 as stock trades -48.0% from 52-week high

Robert I Blum, President & CEO of Cytokinetics, sold 11,500 shares at $55.17 on 2024-08-12, reducing his holdings from 410.9K to 399.4K shares. The company is trading significantly below its 52-week high of $108.06 and has reported a revenue decline of -92.0% year-over-year with a net loss of $-143.3M in the latest fiscal year. Blum's cross-ticker track record shows a 71.43% well-timed rate on 13 prior sales, suggesting some pattern of selling ahead of declines; however, at CYTK specifically, prior sales occurring from June through July have not yet shown negative 90-day returns measurable against the current position. The transaction occurs against a backdrop of deteriorating fundamentals and depressed valuation, though it represents a modest -2.8% reduction in his equity stake.